Annexon to Present Vonaprument Data From ARCHER II
BRISBANE, Calif. — September 24, 2026 Annexon, Inc. announced that it will present two oral presentations on vonaprument at...
geographic atrophy
Advertisement
One04 Therapeutics Launches With CPV-104 Clinical Expansion
FREIBURG, Germany — September 15, 2026 One04 Therapeutics GmbH & Co. KG announced its launch as a clinical-stage biopharmaceutical...
Ocugen Advances OCU410 into Phase 3 Gene Therapy Trial
MALVERN, Pa., Sept. 1, 2026 Ocugen, Inc. has announced that the first patient has been dosed in the global...
Ocugen Receives FDA RMAT Designation for OCU410 in Geographic Atrophy
MALVERN, Pa., July 29, 2026 Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Belite Bio Reports Positive Phase 3 Tinlarebant Data at ASRS 2026
SAN DIEGO, July 20, 2026 Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase...
Advertisements
Inflammasome Reports Positive Phase 2 K8 Results
NEWTON, Mass., July 17, 2026 Inflammasome Therapeutics announced positive six-month Phase 2 clinical trial results for K8 (kamuvudine-8), its...
Annexon Advances Vonaprument with Phase 2 Data
BRISBANE, Calif., July 14, 2026 Annexon announced that new analyses from its Phase 2 ARCHER trial evaluating vonaprument in...
Belite Bio Highlights DRAGON Trial at ISCEV and ASRS
SAN DIEGO, July 6, 2026 Belite Bio announced that new clinical data from its Phase 3 DRAGON trial evaluating...
Nanoscope Therapeutics Partners With McKesson for Retinal Therapy
DALLAS, May 27, 2026 Nanoscope Therapeutics Inc., a biotechnology company developing disease-agnostic therapies for retinal degeneration and vision impairment,...
Renerva Implants First PNM-CAP Device for Neuroma Pain
PITTSBURGH, May 13, 2026 Renerva, Inc. announced the successful first-in-human implantation of its investigational PNM-CAP™ device, marking a major...
Advertisement
